Early treatment with dapsone after spinal cord injury in rats decreases the inflammatory response and promotes long-term functional recovery
Por:
Calderon-Estrella, Francisco, Franco-Bourland, Rebecca E., Rios, Camilo, de Jesus-Nicolas, Diana, Pineda, Benjamin, Mendez-Armenta, Marisela, Mata-Bermudez, Alfonso, Diaz-Ruiz, Araceli
Publicada:
1 abr 2023
Categoría:
Multidisciplinary
Resumen:
Failure of therapeutic strategies for the management and recovery from
traumatic spinal cord injury (SCI) is a serious concern. Dapsone (DDS)
has been reported as a neuroprotective drug after SCI, although the
phase after SC damage (acute or chronic) of its major impact on
functional recovery has yet to be defined. Here, we evaluated DDS
acute-phase anti-inflammatory effects and their impact on early
functional recovery, one week after moderate SCI, and late functional
re-covery, 7 weeks thereafter. Female Wistar rats were randomly assigned
to each of five experi-mental groups: sham group; four groups of rats
with SCI, treated with DDS (0, 12.5, 25.0, and 37.5 mg/kg ip), starting
3 h after injury. Plasma levels of GRO/KC, and the number of neutrophils
and macrophages in cell suspensions from tissue taken at the site of
injury were measured as inflammation biomarkers. Hindlimb motor function
of injured rats given DDS 12.5 and 25.0 mg/ kg daily for 8 weeks was
evaluated on the BBB open-field ordinal scale. Six hours after injury
all DDS doses decreased GRO/KC plasma levels; 24 h after injury,
neutrophil numbers decreased with DDS doses of 25.0 and 37.5 mg/kg;
macrophage numbers decreased only at the 37.5 mg/kg dose. In the acute
phase, functional recovery was dose-dependent. Final recovery scores
were 57.5 and 106.2% above the DDS-vehicle treated control group,
respectively. In conclusion, the acute phase dose-dependent
anti-inflammatory effects of DDS impacted early motor function recovery
affecting final recovery at the end of the study.
Filiaciones:
Calderon-Estrella, Francisco:
Posgrado en Ciencias Biológicas de la Facultad de Ciencias, Universidad Nacional Autónoma de México, Ciudad de México, 04369, Mexico
Franco-Bourland, Rebecca E.:
Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, 14389, Mexico
Rios, Camilo:
Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, 14389, Mexico
Laboratorio de Neurofarmacología Molecular, Universidad Autónoma Metropolitana Xochimilco, Ciudad de México, 04960, Mexico
de Jesus-Nicolas, Diana:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, 14269, Mexico
Pineda, Benjamin:
Laboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, 14269, Mexico
Mendez-Armenta, Marisela:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, 14269, Mexico
Mata-Bermudez, Alfonso:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, 14269, Mexico
Diaz-Ruiz, Araceli:
Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, 14269, Mexico
Green Published, gold, Gold
|